Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use INPEFA safely and effectively. See full prescribing information for INPEFA.INPEFA® (sotagliflozin) tablets, for oral useInitial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
- generic_name
- sotagliflozin
- product_names
- sotagliflozin
- ndc
- 70183-220, 70183-220-30, 70183-220-07, 70183-220-90, 70183-221, 70183-221-30, 70183-221-31, 70183-221-07, 70183-241, 70183-241-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en